A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with the BRAF V600E mutation.
New Hope for Metastatic Colorectal Cancer Patients: A Targeted Approach With a Drug Called Encorafenib Gets FDA Approval
Posted in biotech/medical